Huaijun Wang1, Osamu F Kaneko, Lu Tian, Dimitre Hristov, Jürgen K Willmann. 1. From the Departments of *Radiology, Molecular Imaging Program at Stanford, School of Medicine, †Health, Research and Policy, and ‡Radiation Oncology, Stanford University, Stanford, CA.
Abstract
OBJECTIVES: We sought to assess the feasibility and reproducibility of 3-dimensional ultrasound molecular imaging (USMI) of vascular endothelial growth factor receptor 2 (VEGFR2) expression in tumor angiogenesis using a clinical matrix array transducer and a clinical grade VEGFR2-targeted contrast agent in a murine model of human colon cancer. MATERIALS AND METHODS: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care. Mice with human colon cancer xenografts (n = 33) were imaged with a clinical ultrasound system and transducer (Philips iU22; X6-1) after intravenous injection of either clinical grade VEGFR2-targeted microbubbles or nontargeted control microbubbles. Nineteen mice were scanned twice to assess imaging reproducibility. Fourteen mice were scanned both before and 24 hours after treatment with either bevacizumab (n = 7) or saline only (n = 7). Three-dimensional USMI data sets were retrospectively reconstructed into multiple consecutive 1-mm-thick USMI data sets to simulate 2-dimensional imaging. Vascular VEGFR2 expression was assessed ex vivo using immunofluorescence. RESULTS: Three-dimensional USMI was highly reproducible using both VEGFR2-targeted microbubbles and nontargeted control microbubbles (intraclass correlation coefficient, 0.83). The VEGFR2-targeted USMI signal significantly (P = 0.02) decreased by 57% after antiangiogenic treatment compared with the control group, which correlated well with ex vivo VEGFR2 expression on immunofluorescence (ρ = 0.93, P = 0.003). If only central 1-mm tumor planes were analyzed to assess antiangiogenic treatment response, the USMI signal change was significantly (P = 0.006) overestimated by an average of 27% (range, 2%-73%) compared with 3-dimensional USMI. CONCLUSIONS: Three-dimensional USMI is feasible and highly reproducible and allows accurate assessment and monitoring of VEGFR2 expression in tumor angiogenesis in a murine model of human colon cancer.
OBJECTIVES: We sought to assess the feasibility and reproducibility of 3-dimensional ultrasound molecular imaging (USMI) of vascular endothelial growth factor receptor 2 (VEGFR2) expression in tumor angiogenesis using a clinical matrix array transducer and a clinical grade VEGFR2-targeted contrast agent in a murine model of humancolon cancer. MATERIALS AND METHODS: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care. Mice with humancolon cancer xenografts (n = 33) were imaged with a clinical ultrasound system and transducer (Philips iU22; X6-1) after intravenous injection of either clinical grade VEGFR2-targeted microbubbles or nontargeted control microbubbles. Nineteen mice were scanned twice to assess imaging reproducibility. Fourteen mice were scanned both before and 24 hours after treatment with either bevacizumab (n = 7) or saline only (n = 7). Three-dimensional USMI data sets were retrospectively reconstructed into multiple consecutive 1-mm-thick USMI data sets to simulate 2-dimensional imaging. Vascular VEGFR2 expression was assessed ex vivo using immunofluorescence. RESULTS: Three-dimensional USMI was highly reproducible using both VEGFR2-targeted microbubbles and nontargeted control microbubbles (intraclass correlation coefficient, 0.83). The VEGFR2-targeted USMI signal significantly (P = 0.02) decreased by 57% after antiangiogenic treatment compared with the control group, which correlated well with ex vivo VEGFR2 expression on immunofluorescence (ρ = 0.93, P = 0.003). If only central 1-mm tumor planes were analyzed to assess antiangiogenic treatment response, the USMI signal change was significantly (P = 0.006) overestimated by an average of 27% (range, 2%-73%) compared with 3-dimensional USMI. CONCLUSIONS: Three-dimensional USMI is feasible and highly reproducible and allows accurate assessment and monitoring of VEGFR2 expression in tumor angiogenesis in a murine model of humancolon cancer.
Authors: Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Johan R de Jong; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G E de Vries Journal: Cancer Res Date: 2010-11-17 Impact factor: 12.701
Authors: Alexander R Guimaraes; Robert Ross; Jose L Figuereido; Peter Waterman; Ralph Weissleder Journal: Mol Imaging Biol Date: 2011-04 Impact factor: 3.488
Authors: Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Jianhua Zhou; Huiping Zhang; Huaijun Wang; Amelie M Lutz; Ahmed El Kaffas; Lu Tian; Dimitre Hristov; Jürgen K Willmann Journal: Angiogenesis Date: 2017-07-18 Impact factor: 9.596
Authors: Hua Zhang; Elizabeth S Ingham; M Karen J Gagnon; Lisa M Mahakian; Jingfei Liu; Josquin L Foiret; Juergen K Willmann; Katherine W Ferrara Journal: Biomaterials Date: 2016-11-21 Impact factor: 12.479
Authors: Jianhua Zhou; Huaijun Wang; Huiping Zhang; Amelie M Lutz; Lu Tian; Dimitre Hristov; Jürgen K Willmann Journal: Cancer Res Date: 2016-05-20 Impact factor: 12.701
Authors: Giselle A Suero-Abreu; Orlando Aristizábal; Benjamin B Bartelle; Eugenia Volkova; Joe J Rodríguez; Daniel H Turnbull Journal: Mol Imaging Biol Date: 2017-04 Impact factor: 3.488